CytomX Therapeutics, Inc. Research and Development Expense
CytomX Therapeutics, Inc. (CTMX) reported Research and Development Expense of $17.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- CytomX Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $17.60M, a 32.10% increase year-over-year.
- CytomX Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $19.24M, a 1.96% increase year-over-year.
- CytomX Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $21.23M, a 43.58% increase year-over-year.
- CytomX Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $15.30M, a 28.38% decline year-over-year.
- CytomX Therapeutics, Inc. research and development expense for fiscal 2025 was $68.73M, a 17.57% decline from fiscal 2024.
- CytomX Therapeutics, Inc. research and development expense for fiscal 2024 was $83.38M, a 7.34% increase from fiscal 2023.
- CytomX Therapeutics, Inc. research and development expense for fiscal 2023 was $77.68M, a 30.42% decline from fiscal 2022.
- CytomX Therapeutics, Inc. research and development expense for fiscal 2022 was $111.65M, a 2.23% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $17.60M 10-Q · filed 2026-08-06 | $36.84M 10-Q · filed 2026-08-06 | $58.07M derived: sum of 3 quarters · filed 2026-08-06 | $73.38M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $19.24M 10-Q · filed 2026-05-07 | $40.47M derived: sum of 2 quarters · filed 2026-05-07 | $55.78M derived: sum of 3 quarters · filed 2026-05-07 | $69.10M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $21.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $36.54M derived: sum of 2 quarters · filed 2026-03-16 | $49.86M derived: sum of 3 quarters · filed 2026-08-06 | $68.73M 10-K · filed 2026-03-16 | ||
| 2025-09-30 | $15.30M 10-Q · filed 2025-11-06 | $28.63M derived: sum of 2 quarters · filed 2026-08-06 | $47.49M 10-Q · filed 2025-11-06 | $62.28M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $13.32M 10-Q · filed 2026-08-06 | $32.19M 10-Q · filed 2026-08-06 | $46.98M derived: sum of 3 quarters · filed 2026-08-06 | $68.35M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $18.87M 10-Q · filed 2026-05-07 | $33.66M derived: sum of 2 quarters · filed 2026-05-07 | $55.03M derived: sum of 3 quarters · filed 2026-05-07 | $80.20M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $14.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $36.16M derived: sum of 2 quarters · filed 2026-03-16 | $61.33M derived: sum of 3 quarters · filed 2026-03-16 | $83.38M 10-K · filed 2026-03-16 | ||
| 2024-09-30 | $21.37M 10-Q · filed 2025-11-06 | $46.54M derived: sum of 2 quarters · filed 2025-11-06 | $68.59M 10-Q · filed 2025-11-06 | $87.98M derived: sum of 4 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $25.17M 10-Q · filed 2025-08-07 | $47.22M 10-Q · filed 2025-08-07 | $66.61M derived: sum of 3 quarters · filed 2025-08-07 | $83.06M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $22.05M 10-Q · filed 2025-05-12 | $41.44M derived: sum of 2 quarters · filed 2025-05-12 | $57.89M derived: sum of 3 quarters · filed 2025-05-12 | $78.56M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $19.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $35.83M derived: sum of 2 quarters · filed 2025-03-06 | $56.51M derived: sum of 3 quarters · filed 2025-03-06 | $77.68M 10-K · filed 2025-03-06 | ||
| 2023-09-30 | $16.45M 10-Q · filed 2024-11-07 | $37.12M derived: sum of 2 quarters · filed 2024-11-07 | $58.29M 10-Q · filed 2024-11-07 | $77.86M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $20.67M 10-Q · filed 2024-08-08 | $41.85M 10-Q · filed 2024-08-08 | $61.41M derived: sum of 3 quarters · filed 2024-08-08 | $91.78M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $21.18M 10-Q · filed 2024-05-08 | $40.74M derived: sum of 2 quarters · filed 2024-05-08 | $71.11M derived: sum of 3 quarters · filed 2024-05-08 | $102.27M derived: sum of 4 quarters · filed 2024-05-08 | ||
| 2022-12-31 | $19.56M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $49.93M derived: sum of 2 quarters · filed 2024-03-11 | $81.09M derived: sum of 3 quarters · filed 2024-03-11 | $111.65M 10-K · filed 2024-03-11 | ||
| 2022-09-30 | $30.37M 10-Q · filed 2023-11-07 | $61.53M derived: sum of 2 quarters · filed 2023-11-07 | $92.08M 10-Q · filed 2023-11-07 | $128.66M derived: sum of 4 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $31.16M 10-Q · filed 2023-08-08 | $61.72M 10-Q · filed 2023-08-08 | $98.30M derived: sum of 3 quarters · filed 2023-08-08 | $127.44M derived: sum of 4 quarters · filed 2023-08-08 | ||
| 2022-03-31 | $30.56M 10-Q · filed 2023-05-09 | $67.14M derived: sum of 2 quarters · filed 2023-05-09 | $96.28M derived: sum of 3 quarters · filed 2023-05-09 | $122.38M derived: sum of 4 quarters · filed 2023-05-09 | ||
| 2021-12-31 | $36.58M 10-K/A · filed 2023-03-27 | $65.72M derived: sum of 2 quarters · filed 2023-03-27 | $91.82M derived: sum of 3 quarters · filed 2023-03-27 | $114.19M 10-K/A · filed 2023-03-27 | ||
| 2021-09-30 | $29.14M 10-K/A · filed 2023-03-27 | $55.24M derived: sum of 2 quarters · filed 2023-03-27 | $77.61M 10-K/A · filed 2023-03-27 | $77.61M 10-Q · filed 2021-11-04 | $99.62M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-06-30 | $26.10M 10-K/A · filed 2023-03-27 | $48.47M 10-K/A · filed 2023-03-27 | $48.47M 10-Q · filed 2021-08-05 | $70.48M derived: sum of 3 quarters · filed 2023-03-27 | $94.53M derived: sum of 4 quarters · filed 2023-03-27 | |
| 2021-03-31 | $22.37M 10-K/A · filed 2023-03-27 | $44.38M derived: sum of 2 quarters · filed 2023-03-27 | $68.43M derived: sum of 3 quarters · filed 2023-03-27 | $92.49M derived: sum of 4 quarters · filed 2023-03-27 | ||
| 2020-12-31 | $22.01M 10-K/A · filed 2023-03-27 | $46.06M derived: sum of 2 quarters · filed 2023-03-27 | $70.12M derived: sum of 3 quarters · filed 2023-03-27 | $112.94M 10-K/A · filed 2023-03-27 | ||
| 2020-09-30 | $24.05M 10-K/A · filed 2023-03-27 | $48.12M derived: sum of 2 quarters · filed 2023-03-27 | $90.93M 10-K/A · filed 2023-03-27 | $127.37M derived: sum of 4 quarters · filed 2023-03-27 | ||
| 2020-06-30 | $24.07M 10-K/A · filed 2023-03-27 | $66.88M 10-K/A · filed 2023-03-27 | $103.32M derived: sum of 3 quarters · filed 2023-03-27 | $131.29M derived: sum of 4 quarters · filed 2023-03-27 | ||
| 2020-03-31 | $42.81M 10-K/A · filed 2023-03-27 | $79.25M derived: sum of 2 quarters · filed 2023-03-27 | $107.22M derived: sum of 3 quarters · filed 2023-03-27 | $138.06M derived: sum of 4 quarters · filed 2023-03-27 | ||
| 2019-12-31 | $36.44M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-27 | $64.41M derived: sum of 2 quarters · filed 2023-03-27 | $95.24M derived: sum of 3 quarters · filed 2023-03-27 | $131.62M 10-K/A · filed 2023-03-27 | ||
| 2019-09-30 | $27.97M 10-Q · filed 2020-11-05 | $58.80M derived: sum of 2 quarters · filed 2020-11-05 | $95.18M 10-Q · filed 2020-11-05 | $123.48M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-06-30 | $30.84M 10-Q · filed 2020-08-06 | $67.21M 10-Q · filed 2020-08-06 | $95.52M derived: sum of 3 quarters · filed 2021-02-24 | $123.07M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2019-03-31 | $36.38M 10-Q · filed 2020-05-07 | $64.68M derived: sum of 2 quarters · filed 2021-02-24 | $92.23M derived: sum of 3 quarters · filed 2021-02-24 | $117.78M derived: sum of 4 quarters · filed 2021-02-24 | ||
| 2018-12-31 | $28.31M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $55.85M derived: sum of 2 quarters · filed 2021-02-24 | $81.41M derived: sum of 3 quarters · filed 2021-02-24 | $103.87M 10-K · filed 2021-02-24 | ||
| 2018-09-30 | $27.55M 10-Q · filed 2019-11-07 | $53.10M derived: sum of 2 quarters · filed 2019-11-07 | $75.56M 10-Q · filed 2019-11-07 | $96.26M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-06-30 | $25.55M 10-Q · filed 2019-08-07 | $48.01M 10-Q · filed 2019-08-07 | $68.72M derived: sum of 3 quarters · filed 2020-02-27 | $97.64M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-03-31 | $22.46M 10-Q · filed 2019-05-09 | $43.16M derived: sum of 2 quarters · filed 2020-02-27 | $72.08M derived: sum of 3 quarters · filed 2020-02-27 | $100.16M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $20.70M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $49.62M derived: sum of 2 quarters · filed 2020-02-27 | $77.70M derived: sum of 3 quarters · filed 2020-02-27 | $92.28M 10-K · filed 2020-02-27 | ||
| 2017-09-30 | $28.92M 10-Q · filed 2018-11-06 | $57.00M derived: sum of 2 quarters · filed 2018-11-06 | $71.57M 10-Q · filed 2018-11-06 | $86.92M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-06-30 | $28.08M 10-Q · filed 2018-08-08 | $42.65M 10-Q · filed 2018-08-08 | $58.00M derived: sum of 3 quarters · filed 2019-02-27 | $71.34M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-03-31 | $14.58M 10-Q · filed 2018-05-09 | $29.92M derived: sum of 2 quarters · filed 2019-02-27 | $43.26M derived: sum of 3 quarters · filed 2019-02-27 | $55.97M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2016-12-31 | $15.35M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $28.68M derived: sum of 2 quarters · filed 2019-02-27 | $41.39M derived: sum of 3 quarters · filed 2019-02-27 | $54.76M 10-K · filed 2019-02-27 | ||
| 2016-09-30 | $13.34M 10-Q · filed 2017-11-07 | $26.04M derived: sum of 2 quarters · filed 2017-11-07 | $39.41M 10-Q · filed 2017-11-07 | $48.91M derived: sum of 4 quarters · filed 2018-03-07 | ||
| 2016-06-30 | $12.71M 10-Q · filed 2017-08-07 | $26.07M 10-Q · filed 2017-08-07 | $35.57M derived: sum of 3 quarters · filed 2018-03-07 | $44.73M derived: sum of 4 quarters · filed 2018-03-07 | ||
| 2016-03-31 | $13.37M 10-Q · filed 2017-05-05 | $22.87M derived: sum of 2 quarters · filed 2018-03-07 | $32.02M derived: sum of 3 quarters · filed 2018-03-07 | $37.06M derived: sum of 4 quarters · filed 2018-03-07 | ||
| 2015-12-31 | $9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $18.66M derived: sum of 2 quarters · filed 2018-03-07 | $23.69M derived: sum of 3 quarters · filed 2018-03-07 | $28.36M 10-K · filed 2018-03-07 | ||
| 2015-09-30 | $9.16M 10-Q · filed 2016-11-03 | $14.19M derived: sum of 2 quarters · filed 2016-11-03 | $18.85M 10-Q · filed 2016-11-03 | $23.19M derived: sum of 4 quarters · filed 2017-03-02 | ||
| 2015-06-30 | $5.03M 10-Q · filed 2016-08-03 | $9.70M 10-Q · filed 2016-08-03 | $14.04M derived: sum of 3 quarters · filed 2017-03-02 | $17.95M derived: sum of 4 quarters · filed 2017-03-02 | ||
| 2015-03-31 | $4.66M 10-Q · filed 2016-05-06 | $9.00M derived: sum of 2 quarters · filed 2017-03-02 | $12.92M derived: sum of 3 quarters · filed 2017-03-02 | |||
| 2014-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-02 | $8.26M derived: sum of 2 quarters · filed 2017-03-02 | $28.30M 10-K · filed 2017-03-02 | |||
| 2014-09-30 | $3.92M 10-Q · filed 2015-11-23 | $23.96M 10-Q · filed 2015-11-23 | ||||
| 2013-12-31 | $10.89M 10-K · filed 2016-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |